Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: A nationwide survey

Yonsei Medical Journal

Volumn 51, Issue 2, 2010, Pages 248-252

  Oh, Cheol Young ^a   Lee, Seung Hwan ^b   Yoo, Se Jeong ^b   Chung, Byung Ha ^b  

^a Hallym University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Drug therapy; Physician's practice patterns; Prostate; Prostatic hyperplasia; Prostatic neoplasm

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DECISION MAKING; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PROBABILITY; PROSTATE HYPERTROPHY; QUESTIONNAIRE; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DATA COLLECTION; HUMANS; KOREA; MALE; PROSTATIC HYPERPLASIA; UROLOGY;

EID: 77649198280     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.2.248     Document Type: Article

References (14)

1. Pomer S, Dobrowolski ZF. The therapy of benign prostatic hyperplasia using less-invasive procedures: the current situation. BJU Int 2002;89:773-5.
2. Sountoulides P, Tsakiris P. The evolution of KTP laser vaporization of the prostate. Yonsei Med J 2008;49:189-99.
3. AUA Practice Guidelines Committees. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
4. Irani J, Brown C, Van der Meulen J, Emberton M. [International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool.] Prog Urol 2004;14: 29-32.
5. Irani J, Brown CT, van der Meulen J, Emberton M. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 2003;92:937-42.
6. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54.
7. Nickel JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, et al. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol 2005;12:2677-83.
8. Oelke M, Michel MC, Höfner K. [German guidelines for the assessment of BPH. What's new in 2007?] Urologe A 2008;47: 149-54.
9. Spatafora S, Conti G, Perachino M, Casarico A, Mazzi G, Pappagallo GL; AURO. it BPH Guidelines Committee. Evidencebased guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary. Curr Med Res Opin 2007;23:1715-32.
10. Chung BH, Hong SJ, Cho JS, Seong DH. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 2006;97:742-6.
11. Lee E, Yoo KY, Kim Y, Shin Y, Lee C. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 1998;33:17-21.
12. Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997;158:488-91.
13. Ramsey EW, Elhilali M, Goldenberg SL, Nickel CJ, Norman R, Perreault JP, et al. Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council. J Urol 2000;163:499-502.
14. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2008;62:18-26.